Company Description
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States.
Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice.
It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process.
The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis.
The company markets its products through internet, word of mouth, and sales force to patients and physicians.
The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011.
Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
| Country | United States |
| IPO Date | Feb 2, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 210 |
| CEO | Dr. Ronnie Morris M.D. |
Contact Details
Address: One University Plaza Hackensack, New Jersey United States | |
| Website | https://www.championsoncology.com |
Stock Details
| Ticker Symbol | CSBR |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| CIK Code | 0000771856 |
| CUSIP Number | 15870P307 |
| ISIN Number | US15870P3073 |
| Employer ID | 52-1401755 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ronnie Morris M.D. | Chief Executive Officer & Director |
| David Barry Miller M.B.A. | Chief Financial Officer |
| Dr. Maria Mancini Ph.D. | Chief Operating Officer |
| Arthur Hanson | Vice President of Technology |
| Dr. Karin Abarca Heidemann Ph.D. | Executive Vice President of Global Scientific Operations |
| Dr. Marianna Zipeto Ph.D. | Executive Vice President of Commercial, Research Services & Partnering |
| Dr. Michael Ritchie M.B.A., Ph.D. | Chief Commercial Officer |
| Rachel A. Bunting M.B.A., M.S., MBA, MS | Vice President of Global Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 4 | Filing |
| Nov 18, 2024 | 4 | Filing |
| Nov 18, 2024 | 4 | Filing |
| Nov 18, 2024 | 4 | Filing |
| Nov 18, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 01, 2024 | 4 | Filing |
| Oct 30, 2024 | S-8 | Filing |
| Oct 15, 2024 | 8-K | Current Report |